269 related articles for article (PubMed ID: 30986203)
1. Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis.
Lin P; He RQ; Huang ZG; Zhang R; Wu HY; Shi L; Li XJ; Li Q; Chen G; Yang H; He Y
Aging (Albany NY); 2019 Apr; 11(7):2082-2097. PubMed ID: 30986203
[TBL] [Abstract][Full Text] [Related]
2. m
Hou J; Shan H; Zhang Y; Fan Y; Wu B
Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of aberrant alternative splicing related to carcinogenesis and prognosis of papillary thyroid cancer.
Zheng X; Feng L; Yin Y; Yu C; He X; Zhu J; Zhang M; Yu J; Xu M
Aging (Albany NY); 2021 Oct; 13(19):23149-23168. PubMed ID: 34628367
[TBL] [Abstract][Full Text] [Related]
4. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer.
Wen S; Luo Y; Wu W; Zhang T; Yang Y; Ji Q; Wu Y; Shi R; Ma B; Xu M; Qu N
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1579-1589. PubMed ID: 34693452
[TBL] [Abstract][Full Text] [Related]
5. A Metabolic-associated Nomogram Predicts Recurrence Survival of Thyroid Cancer.
Xi ZH; Ma XX; Chen HY; Yu YH; Li L; Huang T
Curr Med Sci; 2021 Oct; 41(5):1004-1011. PubMed ID: 34510328
[TBL] [Abstract][Full Text] [Related]
6. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma.
Huang Y; Chang A; Zhou W; Zhao H; Zhuo X
Clin Exp Med; 2020 Nov; 20(4):515-525. PubMed ID: 32596748
[TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
8. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
9. Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.
Jin T; Ge L; Chen J; Wang W; Zhang L; Ge M
PeerJ; 2023; 11():e15592. PubMed ID: 37361050
[TBL] [Abstract][Full Text] [Related]
10. Identification of key genes and miRNAs markers of papillary thyroid cancer.
Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer.
Suh HY; Choi H; Paeng JC; Cheon GJ; Chung JK; Kang KW
BMC Cancer; 2019 Dec; 19(1):1260. PubMed ID: 31888560
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
13. The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.
Gu Y; Feng C; Liu T; Zhang B; Yang L
PLoS One; 2018; 13(12):e0209338. PubMed ID: 30576338
[TBL] [Abstract][Full Text] [Related]
14. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
[TBL] [Abstract][Full Text] [Related]
15. The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer.
Xia M; Wang S; Wang L; Mei Y; Tu Y; Gao L
Front Endocrinol (Lausanne); 2023; 14():1062317. PubMed ID: 37025405
[TBL] [Abstract][Full Text] [Related]
16. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
Front Oncol; 2021; 11():705929. PubMed ID: 34722250
[TBL] [Abstract][Full Text] [Related]
18. Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.
Ren N; Tian Z; Sun H; Lu X
Med Sci Monit; 2020 Aug; 26():e924590. PubMed ID: 32827429
[TBL] [Abstract][Full Text] [Related]
19. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer.
Shibata M; Inaishi T; Ichikawa T; Shimizu D; Soeda I; Takano Y; Takeuchi D; Tsunoda N; Kikumori T
Surg Today; 2021 Oct; 51(10):1703-1712. PubMed ID: 33733290
[TBL] [Abstract][Full Text] [Related]
20. A methylomics-associated nomogram predicts recurrence-free survival of thyroid papillary carcinoma.
Chen H; Ma X; Yang M; Wang M; Li L; Huang T
Cancer Med; 2020 Oct; 9(19):7183-7193. PubMed ID: 32783399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
